about
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicRaltegravir cerebrospinal fluid concentrations in HIV-1 infectionAssessment of the pharmacokinetics of co-administered maraviroc and raltegravirPrevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapyHIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integraseReduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages.Nucleoprotein complex intermediates in HIV-1 integrationRaltegravir: molecular basis of its mechanism of action3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.Modeling HIV persistence, the latent reservoir, and viral blips.Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.Rifampin combination therapy for nonmycobacterial infections.HIV-1 integrase inhibitors: a review of their chemical development.In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs).Antiretroviral therapy: effects on orofacial health and health care.Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.Raltegravir as antiretroviral therapy in HIV/AIDS.Discovery of HIV-1 integrase inhibitors: pharmacophore mapping, virtual screening, molecular docking, synthesis, and biological evaluation.Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen.Raltegravir monohydrate.N-hydroxy-substituted 2-aryl acetamide analogs: A novel class of HIV-1 integrase inhibitors.Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.A sensitive liquid chromatography coupled with mass spectrometry method for the intracellular and plasma quantification of raltegravir after solid-phase extraction.Pharmacophore-based database mining for probing fragmental drug-likeness of diketo acid analogues.Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode.
P2860
Q24655011-E36A529D-C228-408B-A902-94B7A046614EQ28476050-6520B445-BA7A-4EF4-9C86-03C621AAB66AQ33696575-FA09899F-D3ED-4D75-9D47-C866B7506685Q34035275-793C072B-5E31-40E1-BEED-2CC9CB2DCB3BQ34233691-AC825095-61A3-4964-A4F9-B2FE66B75621Q34454737-A1CBDD67-E63A-4638-8CD6-FAB62E673E95Q34520239-95AA68AB-D255-4656-97AE-45C98B130A4EQ34770674-BACC0659-1F94-459F-A5DD-6A90F1FC1D81Q35119834-B22B3008-5C0F-4B7C-BAEB-2E651E83DAE4Q35850097-E76F9CAD-DB45-4550-9C74-F5945FD1B645Q36452171-2FC2B1FA-D35F-45EB-9D38-DA0CE79B36D3Q37095708-EEAB70FE-5B16-4226-AE08-37E5A88D6EF2Q37365718-04330417-F9DC-46A1-B076-B5900B1377D8Q37653463-E8F92463-6C49-4F92-BE98-E6FE1F062E8BQ37672039-BB9D8154-B8D9-4D37-B030-BA1CD914A921Q37957767-9862B3CA-B4D3-4EEF-A1F6-6B5FD402347BQ38012389-16E5F4FA-87BC-423B-9F74-3365CADC2E57Q38093238-CA4296A7-E370-4B4A-A7F6-4C947B677925Q38164839-248A9BBA-00FD-457E-A80C-31F06E4B8156Q38168587-3F1E4181-ABE7-456E-83A0-ABB788B7961CQ39108426-BFD64703-7961-46AA-A19F-21F1262223A4Q39328033-CA25E56D-31DC-442B-B2AE-99A5107F94E6Q41831368-B1AEEB1E-ADD4-4FCC-B593-45C58BE280D6Q41984098-5350C4C6-F49B-44D6-991B-5C7BD2B5DD9CQ43108044-309C6100-CDAE-4B71-8CC5-3AEFC8A42DD2Q43227972-A7C2DE68-974D-4393-ACF2-AAC7CCEFA290Q44660027-CD73C84D-B137-4B42-9A11-7883DE54E12FQ45774695-C6F57689-8C11-4BF9-8318-C4685635289AQ45871849-0FD20C99-1DB4-4333-BA36-D1848CDB898CQ49224464-50B0045E-78F4-480D-A9E1-EEE109A289E4
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Raltegravir: the first HIV integrase inhibitor.
@ast
Raltegravir: the first HIV integrase inhibitor.
@en
Raltegravir: the first HIV integrase inhibitor.
@nl
type
label
Raltegravir: the first HIV integrase inhibitor.
@ast
Raltegravir: the first HIV integrase inhibitor.
@en
Raltegravir: the first HIV integrase inhibitor.
@nl
prefLabel
Raltegravir: the first HIV integrase inhibitor.
@ast
Raltegravir: the first HIV integrase inhibitor.
@en
Raltegravir: the first HIV integrase inhibitor.
@nl
P1476
Raltegravir: the first HIV integrase inhibitor.
@en
P2093
Betty J Dong
Jennifer Cocohoba
P304
P356
10.1016/J.CLINTHERA.2008.10.012
P577
2008-10-01T00:00:00Z